239 related articles for article (PubMed ID: 19200867)
1. Long-term experience with induction treatment regimens in multiple sclerosis.
Le Page E; Edan G
J Neurol Sci; 2009 Feb; 277 Suppl 1():S46-9. PubMed ID: 19200867
[TBL] [Abstract][Full Text] [Related]
2. Concepts of induction and escalation therapy in multiple sclerosis.
Rieckmann P
J Neurol Sci; 2009 Feb; 277 Suppl 1():S42-5. PubMed ID: 19200866
[TBL] [Abstract][Full Text] [Related]
3. Rationale for the use of mitoxantrone in multiple sclerosis.
Edan G; Morrissey S; Le Page E
J Neurol Sci; 2004 Aug; 223(1):35-9. PubMed ID: 15261558
[TBL] [Abstract][Full Text] [Related]
4. Induction or escalation therapy for patients with multiple sclerosis?
Le Page E; Edan G
Rev Neurol (Paris); 2018 Jun; 174(6):449-457. PubMed ID: 29799415
[TBL] [Abstract][Full Text] [Related]
5. Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis.
Vollmer T; Panitch H; Bar-Or A; Dunn J; Freedman MS; Gazda SK; Campagnolo D; Deutsch F; Arnold DL
Mult Scler; 2008 Jun; 14(5):663-70. PubMed ID: 18424479
[TBL] [Abstract][Full Text] [Related]
6. A double blind, placebo-controlled, phase II, add-on study of cyclophosphamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-beta study denomination: CYCLIN.
Patti F; Amato MP; Filippi M; Gallo P; Trojano M; Comi GC
J Neurol Sci; 2004 Aug; 223(1):69-71. PubMed ID: 15261564
[TBL] [Abstract][Full Text] [Related]
7. Immunosuppression followed by immunomodulation.
Boggild M
J Neurol Sci; 2009 Feb; 277 Suppl 1():S50-4. PubMed ID: 19200868
[TBL] [Abstract][Full Text] [Related]
8. Preliminary analysis of a trial of pulse cyclophosphamide in IFN-beta-resistant active MS.
Smith D
J Neurol Sci; 2004 Aug; 223(1):73-9. PubMed ID: 15261565
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study.
Cadavid D; Wolansky LJ; Skurnick J; Lincoln J; Cheriyan J; Szczepanowski K; Kamin SS; Pachner AR; Halper J; Cook SD
Neurology; 2009 Jun; 72(23):1976-83. PubMed ID: 19279320
[TBL] [Abstract][Full Text] [Related]
10. The argument against the use of cyclophosphamide and mitoxantrone in the treatment of multiple sclerosis.
Jeffery DR
J Neurol Sci; 2004 Aug; 223(1):41-6. PubMed ID: 15261559
[TBL] [Abstract][Full Text] [Related]
11. [Use of mitoxantrone in early multiple sclerosis with malignant disease course. Observational study in 30 patients with clinical and MRI outcomes after one year].
Ory S; Debouverie M; Le Page E; Pelletier J; Malikova I; Gout O; Roullet E; Vermersch P; Edan G
Rev Neurol (Paris); 2008 Dec; 164(12):1028-34. PubMed ID: 18808781
[TBL] [Abstract][Full Text] [Related]
12. Induction versus escalation therapy.
Martinelli V; Comi G
Neurol Sci; 2005 Dec; 26 Suppl 4():S193-9. PubMed ID: 16388357
[TBL] [Abstract][Full Text] [Related]
13. Serial combination therapy: is immune modulation in multiple sclerosis enhanced by initial immune suppression?
Bar-Or A; Oger J; Gibbs E; Niino M; Aziz T; Renoux C; Alatab S; Shi FD; Campagnolo D; Jalili F; Rhodes S; Yamashita T; Fan B; Freedman MS; Panitch H; Arnold DL; Vollmer T
Mult Scler; 2009 Aug; 15(8):959-64. PubMed ID: 19667022
[TBL] [Abstract][Full Text] [Related]
14. New options for early treatment of multiple sclerosis.
Tintoré M
J Neurol Sci; 2009 Feb; 277 Suppl 1():S9-S11. PubMed ID: 19200870
[TBL] [Abstract][Full Text] [Related]
15. Lessons from randomised direct comparative trials.
Achiron A; Fredrikson S
J Neurol Sci; 2009 Feb; 277 Suppl 1():S19-24. PubMed ID: 19200860
[TBL] [Abstract][Full Text] [Related]
16. Induction therapy for patients with multiple sclerosis: why? When? How?
Edan G; Le Page E
CNS Drugs; 2013 Jun; 27(6):403-9. PubMed ID: 23657788
[TBL] [Abstract][Full Text] [Related]
17. [Newer disease--modifying drugs: glatiramer acetate and mitoxantrone].
Kohriyama T; Higaki M; Matsumoto M
Nihon Rinsho; 2003 Aug; 61(8):1381-7. PubMed ID: 12962027
[TBL] [Abstract][Full Text] [Related]
18. Disease-modifying drugs for the early treatment of multiple sclerosis.
Flachenecker P
Expert Rev Neurother; 2004 May; 4(3):455-63. PubMed ID: 15853542
[TBL] [Abstract][Full Text] [Related]
19. [Long-term effects of glatiramer acetate in multiple sclerosis].
Brochet B
Rev Neurol (Paris); 2008 Nov; 164(11):917-26. PubMed ID: 18790510
[TBL] [Abstract][Full Text] [Related]
20. [Pharmacological treatment of multiple sclerosis].
Myhr KM
Tidsskr Nor Laegeforen; 2010 Mar; 130(5):490-2. PubMed ID: 20224616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
